Cargando…

(18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum

PURPOSE: Recent evidence suggests that PET imaging with amyloid-β (Aβ) tracers can be used to assess myelin integrity in cerebral white matter (WM). Alzheimer’s disease (AD) is characterized by myelin changes that are believed to occur early in the disease course. Nevertheless, the extent to which d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moscoso, Alexis, Silva-Rodríguez, Jesús, Aldrey, Jose Manuel, Cortés, Julia, Pías-Peleteiro, Juan Manuel, Ruibal, Álvaro, Aguiar, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921113/ https://www.ncbi.nlm.nih.gov/pubmed/34581847 http://dx.doi.org/10.1007/s00259-021-05493-y

Ejemplares similares

Prediction of Alzheimer's disease dementia with MRI beyond the short-term: Implications for the design of predictive models
por: Moscoso, Alexis, et al.
Publicado: (2019)

Hybrid (18)F-florbetapir PET/MRI for assessing myelin recovery in GFAP-A patients
por: Meng, Huanyu, et al.
Publicado: (2022)

Spill-in counts in the quantification of (18)F-florbetapir on Aβ-negative subjects: the effect of including white matter in the reference region
por: López-González, Francisco Javier, et al.
Publicado: (2019)

A Systematic Review of PET Textural Analysis and Radiomics in Cancer
por: Piñeiro-Fiel, Manuel, et al.
Publicado: (2021)

Operationalizing the centiloid scale for [(18)F]florbetapir PET studies on PET/MRI
por: Coath, William, et al.
Publicado: (2023)

(18)F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study
por: Zhang, Min, et al.
Publicado: (2021)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
por: Saint-Aubert, Laure, et al.
Publicado: (2013)

Radiation dosimetry of florbetapir F 18
por: Joshi, Abhinay D, et al.
Publicado: (2014)

[(18)F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer’s Disease: A PET Study
por: Planton, Mélanie, et al.
Publicado: (2020)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

(18)F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis
por: Zhang, Min, et al.
Publicado: (2019)

The use of back propagation neural networks and (18)F-Florbetapir PET for early detection of Alzheimer’s disease using Alzheimer’s Disease Neuroimaging Initiative database
por: Ozsahin, Ilker, et al.
Publicado: (2019)

Dual-phase [18F]florbetapir in frontotemporal dementia
por: Asghar, Michael, et al.
Publicado: (2018)

Clinical impact of amyloid PET using (18)F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
por: Matsuda, Hiroshi, et al.
Publicado: (2022)

Tracer‐specific reference tissues selection improves detection of (18)F‐FDG, (18)F‐florbetapir, and (18)F‐flortaucipir PET SUVR changes in Alzheimer's disease
por: Li, Yanxiao, et al.
Publicado: (2022)

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
por: Doraiswamy, P M, et al.
Publicado: (2014)

PET imaging of 18F-florbetapir in cognitively impaired individuals: Lack of activity within the cerebellar cortex
por: Meyer, Michael A., et al.
Publicado: (2018)

Biomarkers Assessing Endothelial Dysfunction in Alzheimer’s Disease
por: Custodia, Antía, et al.
Publicado: (2023)

Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
por: Camus, V., et al.
Publicado: (2012)

A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir
por: Osborne, Dustin R., et al.
Publicado: (2015)

Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis
por: Sperry, Brett W., et al.
Publicado: (2021)

Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer’s Disease and Other Neurodegenerative Diseases
por: Custodia, Antía, et al.
Publicado: (2022)

Repeatability of parametric methods for [(18)F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study
por: Verfaillie, Sander CJ, et al.
Publicado: (2020)

Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers
por: Burgos, Ninon, et al.
Publicado: (2015)

SimPET—An open online platform for the Monte Carlo simulation of realistic brain PET data. Validation for (18)F‐FDG scans
por: Paredes‐Pacheco, José, et al.
Publicado: (2021)

Brain Atrophy and Clinical Characterization of Adults With Mild Cognitive Impairment and Different Cerebrospinal Fluid Biomarker Profiles According to the AT(N) Research Framework of Alzheimer’s Disease
por: Rivas-Fernández, Miguel Ángel, et al.
Publicado: (2022)

The Role of Inflammatory Diet and Vitamin D on the Link between Periodontitis and Cognitive Function: A Mediation Analysis in Older Adults
por: Botelho, João, et al.
Publicado: (2021)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Lacrimal gland uptake on F-18 florbetapir amyloid positron emission tomography scan
por: Itani, Malak, et al.
Publicado: (2017)

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds
por: Wagner, T., et al.
Publicado: (2018)

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study
por: Ramanan, Vijay K., et al.
Publicado: (2013)

A consecutive case series experience with [(18) F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
por: Mitsis, Effie M, et al.
Publicado: (2014)

Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2018)

Development of software for measuring brain amyloid accumulation using (18)F‐florbetapir PET and calculating global Centiloid scale and regional Z‐score values
por: Matsuda, Hiroshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ig8ucl2to4pja49pa76ndd8jpi